Skip to content

Sonazoid-enhanced Ultrasound for the Detection of Colorectal Liver Metastases Less Than 2 cm

Evaluation of Contrast Sonazoid-enhanced Ultrasound for the Detection of Colorectal Liver Metastases Less Than 2 cm

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04686942
Enrollment
550
Registered
2020-12-29
Start date
2020-12-17
Completion date
2023-12-30
Last updated
2020-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Metastasis Colon Cancer

Brief summary

Preoperative chemotherapy is often used for patients with colorectal cancer liver metastasis (CLM). Many small CLMs (\<=2cm) may disappear after chemotherapy, while most of these are still alive. Ultrasonography (US) is a common imaging modality for the intraoperative detection tumor. Sonazoid is new echo-contrast agent, which is more stable and sensitive for detecting of small tumor. Investigators initially this prospective study to compare the detection performance before and after using sonazoid.

Interventions

DIAGNOSTIC_TESTAfter sonazoid

0.015ml/mg sonazoid enhanced US to detection of liver metastases.

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Pathology confirmed colorectal adenocarcinoma * One or more liver metastases less than 2 cm * Multidisciplinary team recommend to perform preoperative chemotherapy * Have baseline EOB-MR before chemotherapy

Exclusion criteria

* Could not fulfill the criteria of no evidence of disease (NED) after hepatic resection/ablation/radiotherapy * With other malignancies

Design outcomes

Primary

MeasureTime frameDescription
sensitive of detection tumor6 monthsChange of the sensitivity detection liver tumors when using sonazoid enhanced ultrasound

Countries

China

Contacts

Primary ContactJiliang Qiu
qiujl@sysucc.org.cn862087343114
Backup ContactXuzhi Pan
panxzh@sysucc.org.cn862087343009

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026